Skip to main content

Table 2 Individual study results. Descriptive data, Mean and standard deviation for adult height and net height gain

From: Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis

Study Sample size Mean age baseline yrs (SD) Mean BA baseline yrs (SD) Mean MPH Intervention Dose of Ox (mg/kg/day) Mean time on Ox yrs Mean AH cm (SD) Mean Ht gain Cm (SD) Age at estrogen initiation Yrs (SD) Puberty Sp (%)
Menke [33] 42 8.5 (4.0) 8.1 (3.6) NR GH + Ox 0.03 6 156.7 (7.2) 9.5 (4.7) 12.8 (0.9) 21
  36 9.1 (3.5) 8.8 (3.4) NR GH + Ox 0.06 6 156.5 (5.8) 8.3 (4.7) 12.7 (0.9) 24
  42 9.4 (3.8) 9.0 (3.4) NR GH + Placebo   - 155.6 (5.4) 7.2 (4) 12.9 (1.0) 25
Gault [34] 47 10.2 (1.1) NR NR GH + Ox 0.05 5 151.06 (4.53) - 12 (N = 12) 14 (N = 24) 23
  52 10.3 (0.9) NR NR GH + Placebo   - 149.72 (6.75) - 12 (N = 17) 14 (N = 28) 13
Rosenfeld [3] 45 9.9 (2.3) 8 162.5 (4.1) GH + Ox 0.125a 6 152.1 (5.9) 10.3 (4.7) 14.9 (0.9) NR
  17 9.1 (2.1) 8 164.5 (3.7) GH + Placebo   - 150.4 (5.5) 8.4 (4.5) 15.2 (0.9) NR
Stahnke [35] 33 11.8 (2.0) 9.9 (1.0) 166.9 (4.0) GH + Ox 0.1b 4 155.1 (4.5) 7.9 (3.8) 14.9 NR
  38 11.7 (1.8) 9.9 (1.1) 163.6 (4.4) GH + Ox 0.1c - 152.8 (3.8) 6.4 (3.5) 14.9 NR
  20 11.5 (1.2) 10.3 (0.5) 165.1 (5.5) GH + Placebo   - 151.7 (3.1) 3.6 (2.6) 14.9 NR
  1. AH adult height, SD standard deviation, Ox oxandrolone, Ht height, BA bone age, MPH mid parental height or target height, NR not reported, Sp spontaneous
  2. aDose cut in half after the first two years of therapy
  3. bDose decreased to 0.05 mg/kg/day after the first year
  4. ctransient oxandrolone group, given ox for < 1 year due to side effects